Marko Virtanen
A5071638295- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Aortic Disease and Treatment Approaches
- Cardiovascular Function and Risk Factors
- Blood Pressure and Hypertension Studies
- Cardiac Imaging and Diagnostics
- Cardiovascular Health and Disease Prevention
- Atrial Fibrillation Management and Outcomes
- Cardiac Structural Anomalies and Repair
- Heart Rate Variability and Autonomic Control
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiac tumors and thrombi
- Ultrasound and Hyperthermia Applications
- Cardiovascular and Diving-Related Complications
- Infectious Aortic and Vascular Conditions
- Nutrition and Health in Aging
- Electroconvulsive Therapy Studies
- Congenital Heart Disease Studies
- Acute Ischemic Stroke Management
- Vasculitis and related conditions
- Ultrasound Imaging and Elastography
- Mechanical Circulatory Support Devices
- Cardiac and Coronary Surgery Techniques
- Takotsubo Cardiomyopathy and Associated Phenomena
- Renal and Vascular Pathologies
Tampere University
2012-2025
Tampere University Hospital
2012-2025
University of Helsinki
2023
Helsinki University Hospital
2023
Society of Thoracic Surgeons
2020
Guidelines •
The aim of this study was to evaluate the incidence and prognostic impact paravalvular regurgitation (PVR) on outcome after transcatheter (TAVR) surgical aortic valve replacement (SAVR) for stenosis.The nationwide FinnValve registry included data 6463 consecutive patients who underwent TAVR (n = 2130) or SAVR 4333) with a bioprosthesis treatment stenosis during 2008-2017. PVR at discharge 4-year mortality herein investigated.The rate mild 21.7% 5.2% SAVR. moderate-to-severe 3.7% 0.7% After...
The aim of this study was to compare the risk prosthetic valve endocarditis (PVE) in patients with transcatheter aortic replacement (TAVR) or surgical (SAVR).The FinnValve registry included data from 6,463 consecutive who underwent TAVR (n=2,130) SAVR (n=4,333) a bioprosthesis 2008 2017. PVE defined according modified Duke criteria. In study, incidence 3.4/1,000 person-years after TAVR, and 2.9/1,000 SAVR. competing analysis there no significant difference between over an eight-year...
<h3>Importance</h3> Transcatheter aortic valve replacement (TAVR) has been shown to be a valid alternative surgical (SAVR) in patients at high operative risk with severe stenosis (AS). However, the evidence of benefits and harms TAVR low is still scarce. <h3>Objective</h3> To compare short-term midterm outcomes after SAVR low-risk AS. <h3>Design, Setting, Participants</h3> This retrospective comparative effectiveness cohort study used data from Nationwide Finnish Registry Surgical Aortic...
Abstract Objectives To compare the outcomes after surgical (SAVR) and transcatheter aortic valve replacement (TAVR) for severe stenosis of bicuspid (BAV). Methods We evaluated early mid-term outcome patients with stenotic BAV who underwent SAVR or TAVR from nationwide FinnValve registry. Results The registry included 6463 AS 1023 (15.8%) them had BAV. was performed in 920 103 In overall series, device success comparable to (94.2% vs. 97.1%, p = 0.115). associated increased rate...
Incidence of cryptogenic ischemic stroke (CIS) in young adults is increasing. Early left atrial (LA) myopathy might be 1 the underlying mechanisms, but this has only been scarcely explored.
BACKGROUND: The incidence of young-onset ischemic stroke is rising, driven by cryptogenic (CIS) and patients without vascular risk factors. This study examines the burden associations modifiable traditional, nontraditional, female sex–specific factors with CIS, stratified clinically relevant patent foramen ovale (PFO), defined high-risk features atrial septal aneurysm or large right-to-left shunt. METHODS: We enrolled consecutive aged 18 to 49 years recent CIS frequency-matched stroke-free...
Aim: We investigated the outcomes of transcatheter (TAVR) and surgical aortic valve replacement (SAVR) in Finland during last decade.Methods: The nationwide FinnValve registry included data from 6463 patients who underwent TAVR or SAVR with a bioprosthesis for stenosis 2008 to 2017.Results: annual number treated increased three-fold study period. Thirty-day mortality declined 4.8% 1.2% (p = .011) 4.1% 1.8% .048). Two-year survival improved 71.4% 83.9% < .001) 87.2% 91.6% .006). During...
<h3>Background</h3> While transcatheter aortic valve implantation (TAVI) is established for treating high-operative risk surgical replacement candidates, until recently the smallest heart (THV) measured 23 mm, posing greater annular rupture and THV failure in patients with stenosis (AS) small annuli (≤20 mm). <h3>Objectives</h3> In setting of a multicentre registry, we report on safety, efficacy early clinical outcomes SAPIEN XT 20 mm balloon-expanding THV. <h3>Results</h3> Among TAVI 55...
Abstract Background Conduction defects requiring permanent pacemaker (PPM) implantation are frequent complications occurring after surgical (SAVR) and transcatheter aortic valve replacement (TAVR). Methods Patients who underwent TAVR or SAVR with a bioprosthesis from the nationwide FinnValve registry were subjects of this study. prior PPM, received sutureless prosthesis, required cardiac resynchronization therapy implantable cardioverter defibrillator excluded analysis. Results Four thousand...
Abstract Background Patients with severe aortic stenosis and left ventricular systolic dysfunction have a poor prognosis, this may result in inferior survival also after valve replacement. The outcomes of transcatheter surgical replacement were investigated comparative analysis. Methods retrospective nationwide FinnValve registry included data on patients who underwent or bioprosthesis for stenosis. Propensity score matching was performed to adjust the baseline covariates reduced (≤ 50%)...
Background:The aim of this study was to investigate the impact anatomical site status and major vascular complication (MVC) severity on outcome transfemoral transcatheter aortic valve replacement (TF-TAVR).